STOCK TITAN

Jurgi Camblong (SOPH) reports multiple 10b5-1 sales across late 2025–2026

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

SOPH reports multiple Rule 10b5-1 sales by Jurgi Camblong. The filing lists numerous planned sales of Common stock executed under a 10b5-1 plan between 12/19/2025 and 03/13/2026, including 95,488 shares on 01/09/2026 (amount 491,626.46) and 37,299 shares on 01/22/2026 (amount 209,917.83).

Positive

  • None.

Negative

  • None.

Insights

Notice lists routine 10b5-1 sales by a reporting person.

The filing catalogs multiple scheduled sales by Jurgi Camblong executed under a 10b5-1 plan across late 2025 and early 2026. The entries show share counts and corresponding proceeds figures for each trade date, indicating systematic dispositions.

Cash‑flow treatment and any remaining holdings are not stated in the excerpt; subsequent filings may provide post‑transaction positions.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the SOPH Form 144 disclose about insider sales?

The filing discloses multiple 10b5-1 sales by Jurgi Camblong between 12/19/2025 and 03/13/2026, listing per‑trade share counts and proceeds such as 95,488 shares for 491,626.46 on 01/09/2026.

Who executed the sales reported in the SOPH filing?

The reported sales were executed under a 10b5-1 plan by Jurgi Camblong. The entry lines identify the same reporting person and show multiple trade dates with share quantities and corresponding proceeds figures.

Which trade dates and sample quantities appear in the SOPH excerpt?

Sample dates and quantities include 01/09/2026 (95,488 shares; amount 491,626.46) and 01/22/2026 (37,299 shares; amount 209,917.83). The excerpt lists many additional sale dates and amounts.

Does the filing state how the proceeds are treated for SOPH?

The excerpt lists per‑trade amounts but does not state who receives proceeds or how proceeds will be used. The filing shows proceeds figures per sale without specifying recipient treatment in the provided text.
Sophia Genetics Sa

NASDAQ:SOPH

View SOPH Stock Overview

SOPH Rankings

SOPH Latest News

SOPH Latest SEC Filings

SOPH Stock Data

351.89M
67.30M
Health Information Services
Healthcare
Link
Switzerland
Rolle